Novavax Inc (NVAX) FinancialsNVAXNovavax Inc

Novavax, Inc. (NVAX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Licensing Royalties And Other, accounting for 66.7% of total sales, equivalent to $37.84M. Another important revenue stream is Product. Understanding this composition is critical for investors evaluating how NVAX navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Novavax, Inc. maintains a gross margin of 78.93%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -85.55%, while the net margin is -94.16%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively NVAX converts its operational activities into shareholder value.

In the context of the broader market, NVAX competes directly with industry leaders such as MLYS and VERA. With a market capitalization of $2.11B, it holds a leading position in the sector. When comparing efficiency, NVAX's gross margin of 78.93% stands against MLYS's N/A and VERA's N/A. Such benchmarking helps identify whether Novavax, Inc. is trading at a premium or discount relative to its financial performance.

Novavax's total revenue for Q2 2026 was $56,698,000, with a gross margin of 78.93%. Despite these figures, the company has faced volatility in net income, with significant losses reported in several quarters.